(Reuters) – Merck & Co Inc said on Wednesday that the

expected a broad about its drug study data for

Zetia cholesterol will be available in 2014 instead of the

2013.

essay on 18,000 patients, closely followed and

called IMPROVE-IT, it was designed to assess whether combining Zetia

with the oldest of so-called Merck cholesterol drug

Zocor is more effective in reducing heart attacks and

strokes (CVA) than Zocor alone.

Zocor, known generically as simvastatin, is one

similar to Lipitor from Pfizer Inc. Zetia Statin reduces the

cholesterol using a method different. Merck Vytorin combines

both drugs in a single pill, and is the product that is

you are evaluating in the trial.

the questions about combination therapy came

then of that data on a prior trial, known as ENHANCE

they thrown that Vytorin was no more effective at reducing plaque

in the carotid artery that Zocor only and not respond the

question about whether adding Zetia more decreased the rate of heart attacks.

and while Vytorin Yes appeared better in decreasing of the

’bad’ LDL cholesterol, did not generate major changes in other

key measurements in patients with a hereditary form of

high cholesterol known as hypercholesterolemia family.

is stipulated that the IMPROVE-IT trial ends once that

5,250 episodes clinical, as attacks have reported

cardiac or LCA.

in March of this year, driver Security Committee of

trial, an independent, entity data completed a second

preliminary efficacy analysis and recommended not to change the design

of the Studie. und sagte, dass er plante, überprüfen Sie die Daten wieder in

etwa neun Monate.

Merck darauf hingewiesen, dass die Revision nun auf verschoben hatte

März von 2013. basierend auf der aktuellen Rate, bei der sich

Episoden, Unterrichtung, die Firma sagte, es erwartet, dass die Anzahl

Ziel wird im Jahr 2014 erreicht werden.